tomeko

Tubulointerstitial kidney disease, autosomal dominant, 2

Just diagnosed with Tubulointerstitial kidney disease, autosomal dominant, 2?

You are not alone. Here is where to start: learn the basics, find a specialist or center that sees Tubulointerstitial kidney disease, autosomal dominant, 2, look for clinical trials, and connect with others living with it — all in one place.

Open the full Tubulointerstitial kidney disease, autosomal dominant, 2 hub →

Overview

Tubulointerstitial kidney disease, autosomal dominant, 2 is a rare condition. Also known as ADTKD-MUC1, MCKD1, MUC1-related medullary cystic kidney disease, MUCI-related ADTKD, Medullary cystic kidney disease type 1. Tomeko brings together the specialists, research, clinical trials, treatments and community for Tubulointerstitial kidney disease, autosomal dominant, 2 so you can go from overwhelmed to oriented. For authoritative medical detail, see the reference sources below.

Identifiers: ORPHA:88949 · OMIM 174000 · ICD-10 Q61.5 · GARD 0007002

Find care for Tubulointerstitial kidney disease, autosomal dominant, 2

Authoritative references for Tubulointerstitial kidney disease, autosomal dominant, 2

Common questions

I was just diagnosed with Tubulointerstitial kidney disease, autosomal dominant, 2 — what should I do first?

Start by learning the basics from an authoritative source, find a specialist or center that sees Tubulointerstitial kidney disease, autosomal dominant, 2, and connect with a patient organization. Tomeko brings these together on one hub.

Where can I find a specialist for Tubulointerstitial kidney disease, autosomal dominant, 2?

Use Tomeko's specialist and Centers-of-Excellence directories to find clinicians who treat Tubulointerstitial kidney disease, autosomal dominant, 2, filtered to your area.

Are there clinical trials for Tubulointerstitial kidney disease, autosomal dominant, 2?

Tomeko shows live, recruiting studies for Tubulointerstitial kidney disease, autosomal dominant, 2 from ClinicalTrials.gov on the hub.

Informational only — not medical advice. Always consult a qualified clinician. Provider and reference data from public sources (NIH GARD, Orphanet, OMIM, HPO, MONDO, ClinicalTrials.gov, CMS NPPES). © Tomeko · tomekohealth.com